| Accession Number: | 0001209191-23-011282 |
| Date: | 2023-02-16 |
| Issuer: | ATYR PHARMA INC (LIFE) |
| Original Submission Date: |
SHUKLA SANJAY
3545 JOHN HOPKINS COURT, SUITE #250
SAN DIEGO, CA 92121
| Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
|---|
| Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMPLOYEE STOCK OPTION (RIGHT TO BUY) | 2.195 | 2023-02-16 | deemed execution date | A | 336,096 (a) | 2033-02-16 | common stock 336,096 | $2.20 | 336,096 | direct |
| ID | footnote |
|---|---|
| f1 | the shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning march 16, 2023, such that this option will be fully exercisable on february 16, 2027. this option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. |
